Related Experiment Videos
[Therapy control in cardiology: serum level monitoring]
Abstract:
Treatment of cardiac patients with drugs of low therapeutic ratio (i.e. cardiac glycosides, antiarrhythmics) must be individualized to avoid undertreatment or intoxication with their often deleterious consequences. However, in most cases the dose-response effect cannot be predicted, especially in those instances in which the desired effect is hard to measure (e.g. intermittent arrhythmias). Very often a potentially useful drug is not effective because the applied dose is either too low or administered at incorrect intervals. An effective medication can also be incorrectly assumed to be intolerable when the dose administered is too high relative to the patient's impaired renal or liver function. Fixed application schedules will not be successful in the majority of cases due to the following large interpatient variables: absorption, distribution, elimination, biotransformation, protein and tissue binding, and effect on the target organ. If drug efficacy cannot be proven by clinical observation the determination of blood levels of substances with a narrow therapeutic ratio cen be helpful. However, an interpretation should only be made by considering the clinical condition of the patient and the inherent kinetic variables of the drug.
Insights
Individualizing cardiac drug therapy is crucial for patients with low therapeutic ratios to prevent under- or over-dosing. Therapeutic drug monitoring, considering patient factors, is essential when clinical observation is insufficient.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Therapeutics
Context:
- Cardiac medications with narrow therapeutic ratios require precise dosing.
- Individual patient variability significantly impacts drug response.
- Challenges exist in predicting dose-response, especially for intermittent conditions.
Purpose:
- To emphasize the necessity of individualized treatment for cardiac drugs with low therapeutic ratios.
- To highlight the limitations of fixed dosing schedules due to interpatient variables.
- To advocate for therapeutic drug monitoring when clinical efficacy is uncertain.
Summary:
- Drugs with low therapeutic ratios (e.g., cardiac glycosides, antiarrhythmics) demand personalized dosing to avoid toxicity or ineffectiveness.
- Interpatient variability in absorption, distribution, metabolism, and elimination necessitates tailored treatment plans.
- Blood level monitoring can aid efficacy assessment but requires integration with clinical status and pharmacokinetics.
Impact:
- Improved patient outcomes through optimized cardiac drug therapy.
- Reduced risk of adverse drug events and treatment failure.
- Enhanced clinical decision-making in managing cardiac conditions with critical medications.